Editorial
 LANDMARK DECISION ON ASR   
 Monday, December 10, 2018 
 In a landmark decision, the Union Health Ministry on November 29 this year approved a formula for determination of compensation for patients who had received faulty Articular Surface Replacement (ASR) hip implants manufactured by DePuy International Ltd, UK, a subsidiary of Johnson & Johnson (J&J). 
  Past Editorial...  
TODAY'S NEWS
10:00  [IST]Quidel to introduce Triage PLGF Assay in Q1 2019 to diagnosis preterm pre-eclampsia
09:00  [IST]Teething gels for babies and children to be sold only in pharmacies: MHRA
more news >>
TOP NEWS
08:00  [IST]India drafts first national essential diagnostics list; vector-borne diseases, NCDs given high priority
08:00  [IST]Pharmexcil seeks suggestions from exporters to promote and improve pharma exports to African countries
08:00  [IST]Maharashtra Assembly passes bill to amend IPC provisions in line with D&C Act to penalise drug dealers
08:00  [IST]Odisha DCA to launch online portal for submission of applications for grant of licences from December 17
08:00  [IST]Telangana govt to create unique electronic health rerecord of all citizens in state on the lines of Aadhaar
08:00  [IST]Ayush pharmacopoeia standards in digital format to help manufacturers boost drug quality, efficacy
more news >>
YESTERDAY'S NEWS
18:00  [IST]AMAG Pharma to buy US-based biopharma company, Perosphere Pharmaceuticals
17:00  [IST]Minoryx completes patient randomization of phase 2/3 trial of MIN-102 to treat adrenomyeloneuropathy
16:00  [IST]BioArctic gets US FTC nod to outlicense alpha-synuclein antibody portfolio for Parkinson’s disease to AbbVie
15:00  [IST]AZBio receives US$ 299,750 grant from US EDA to support building evergreen seed fund for Arizona-based health innovations
14:00  [IST]Vertex Pharma gets Health Canada marketing approval for Orkambi for children with CF aged 2 to 5 years
22:19  [IST]Delhi High Court revokes govt ban on manufacture, sale of oxytocin by private firms
more news >>
INTERVIEW  
Rising burden of NCDs impacts Indian healthcare scene
Gagan Singh Bedi, managing director, AstraZeneca Pharma India Gagan-Singh-Bedi.jpg
Past Interviews...
 
  What's New?  
 
Opinion Poll
 
 
Will the central govt's decision to replace MCI with National Medical Commission boost the medical education scenario in the country?
  
 
 
   
 
  Corporate
Pharma Stocks
Executive Diary
Pharma People
Product Launches
  Special Features
Features
  Chronicle Pharmabiz Specials
Forthcoming
  Past
 
  Forthcoming Events
International
  Domestic
 
TENDERS & PROJECTS
Tenders & Enquiries
Pharma Projects
CORPORATE
Company Profile
Corporate Results
Corporate X-ray
Pharmabiz Studies of Top Companies
US FDA UPDATE
US FDA: ANDA
US FDA: Warnings
US FDA: Approved NMEs
US FDA: New Approvals
EXPORT & IMPORT
Drug Export Procedures
Drug Units With WHO GMP Certification
Pharma Export Data
Import Reg. Update
PHARMA LAWS & DOCUMENTS
Notifications
Pharma Regulations
Patent Laws and Amendments
Patent Scan
Documents
New Drug Approvals
Notified Prices
LIST OF LABS & GOVT. BODIES
Govt Recognised In-House R&D Units
AICTE Boards & Committees
List of Indian CROs
List of CROs (International)
Govt & approved labs of India
List of State Drugs Controllers
 
 
ipc_2018
BTS_2018
cphi-india_Banner-150x60
 
 
 
 
Copyright © 2016 Saffron Media Pvt. Ltd |